About
Incubate
About Incubate
Our Mission
Overview
Incubate is a 501(c)(4) organization of venture capital firms representing the patient, corporate, and investment communities. Our primary aim is to educate policymakers on the role of venture capital in bringing promising treatments to patients in need.
Mission
We help ensure patients continue to benefit from the unrelenting innovation spurred by venture capital investment in life sciences and protected by America’s intellectual property system.
Why venture capital matters
Learn why venture investment is so vital to developing effective new medical treatments.
Our Priorities
Foster innovation
Help ensure a level global playing field for investment and promote policies that empower life science innovators to build and grow in the United States.
Why It Matters
For America to remain the leader in medical innovation, its business, investment, and policy ecosystems must welcome and support life science innovators from start-ups to major firms.
Safeguard advancements
Strengthen and protect U.S. intellectual property provisions by promoting patent and regulatory systems that encourage life sciences innovation.
Why It Matters
Investment in life science is risky: 9 out of 10 initial treatments are ineffective or don’t recoup their development costs. Protecting the American intellectual property system preserves incentives for the development of new treatments and ensures that the revenue from successful treatments can subsidize continued innovation.
Amplify the results
Spotlight the venture capital-driven breakthroughs that are transforming medicine for patients and health professionals around the globe.
Why It Matters
Amidst the nuanced discussions around healthcare costs in this country, policymakers, providers, and patients all deserve a complete understanding of the factors that contribute to successful development of effective treatments.
Resources
Get valuable information on policy, venture capital, and the life sciences innovation ecosystem.
Our People
Incubate Board Members
Lindsay Androski
President
Laura Gunter
Treasurer
Christine Brennan
Secretary
Advisory Board
Lindsay Androski
M.B.A, J.D.President and CEO,
Roivant Foundation
Roivant Sciences
Christine Brennan
Managing Director,
Vertex Venture HC
John Conrad
President & CEO,
Illinois Biotechnology Innovation Organization (iBIO)
Brian Darmody
CEO,
Association of University Research Parks (AURP)
Barbara Dalton
Ph.DVice President, WWBD and Senior Managing Partner,
Pfizer Ventures
Bart Forsyth
JDVice President,
Federal Advocacy
PhRMA
Gaurav Gupta
M.D., M.S.Managing Partner, Life Sciences Private Capital
Bryan Gutierrez
Principal, Gordian Ventures
Orin Herskowitz
Executive Director, Columbia Technology Ventures; SVP of Applied Innovation and Industry Partnerships, Columbia University
Adam Houghton
Ph.D., M.B.A.Chief Business Officer,
Upstream Bio
Chris Israel
M.B.ASenior Partner,
American Continental Group
Peter Kolchinsky
Ph.D.Managing Partner,
RA Capital Management;
Author of The Biotech Social Contract series on Medium
Gary Lauder
M.B.A.Managing Director,
Lauder Partners
Erin Mistry
EVP and Chief Commercial Officer,
Cormedix
Amy Millman
M.P.A.Founder, Springboard Enterprises
Janis Naeve
Ph.D.Partner
Cota Capital
Imran Nasrullah
M.S. J.DVP & US Head,
Collaborate2Cure Hub, Bayer
Sara Nayeem
M.D.Partner,
Avoro Ventures
Kendalle Burlin O'Connell Esq.
Chief Executive Officer & PresidentMassBio
Emily Roberts
Director,
Issue Advocacy
Genentech
Nancy Sullivan
CEO and Managing Director,
Illinois Ventures
Matt Tremblay
Chief Executive Officer, Blackbird Laboratories
Rose Wang
M.B.A.Executive Advisor,
AIM-HI Accelerator Fund; Founder & CEO 1104Health
Jonathan Weinberger
J.D., M.A.Chief Advocate,
Global Transportation Technology Policy
Peter Young
M.B.A.Life Science Executive & Venture Partner,
Pappas Capital
Our Team
John Stanford
Executive Director
Maggie Ambrose
Director
Grace Moster
Senior Associate